Cadila Healthcare has received permission to conduct clinical trials on its new molecular entity - ZYH1 - a formula to check cholesterol in blood.According to a release issued by Cadila to the BSE, the drug controller general of india (DCGI) gave its approval to conduct Phase I clinical trials to evaluate the safety profile of ZYH1.The clinical trails will be conducted at Zydus research centre, which is equipped to conduct the initial trial."ZYH1 is expected to address the issue related to patients suffering from Dyslipidemia in both diabetic and non-diabetic condition", said B B Lohray, president, Zydus research centre.
